Cargando…
Antitumor activities of Liver-targeting peptide modified Recombinant human Endostatin in BALB/c-nu mice with Hepatocellular carcinoma
In our previous study, a liver-targeting peptide CSP I-plus modified recombinant human Endostatin (rEndostatin, endostar) (rES-CSP) was constructed and showed potent antiangiogenic capability and could specifically bind to human hepatocellular carcinoma cells to make a direct inhibition in vitro. In...
Autores principales: | Yan, Ma, Dongmei, Bao, Jingjing, Zhang, Xiaobao, Jin, Jie, Wang, Yan, Wang, Jiayong, Zhu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658401/ https://www.ncbi.nlm.nih.gov/pubmed/29075040 http://dx.doi.org/10.1038/s41598-017-14320-0 |
Ejemplares similares
-
CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinβ1
por: Chen, Xueqin, et al.
Publicado: (2022) -
Comparison of the antiangiogenic activity of modified RGDRGD-endostatin to endostatin delivered by gene transfer in vivo rabbit neovascularization model
por: Ge, Hong-yan, et al.
Publicado: (2011) -
Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
por: Zhang, Qunling, et al.
Publicado: (2016) -
Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog
por: Wang, Shan, et al.
Publicado: (2016) -
Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice
por: Ma, Xingqun, et al.
Publicado: (2012)